Results 201 to 210 of about 631,547 (339)

Commentary on aptamers for virus research

open access: yesFrontiers in Microbiology, 2012
Yasuyuki eMiyazaki, Mikako eFujita
doaj   +1 more source

PCSK9 Loss‐of‐Function Disrupts Cellular Microfilament Network via LIN28A/HES5/JMY Axis in Neural Tube Defects

open access: yesAdvanced Science, EarlyView.
PCSK9 acts as a molecular chaperone promoting LIN28A lysosomal degradation. LIN28A elevates transcription factor HES5, increasing JMY expression. PCSK9 loss causes neural tube defects (NTDs) by disrupting the LIN28A/HES5/JMY axis, and high JMY disorganizes the neural progenitor cell microfilament network, leading to incomplete neural tube structure in ...
Xiaoshuai Li   +6 more
wiley   +1 more source

Unlocking atom-specific radiotherapy - DNA backbone breakage caused by X-ray photoactivation. [PDF]

open access: yesChem Sci
Svensson PHW   +15 more
europepmc   +1 more source

NEAT1 Promotes Epileptogenesis in Tuberous Sclerosis Complex

open access: yesAdvanced Science, EarlyView.
The primary neurological manifestations of tuberous sclerosis complex (TSC) are intractable epilepsy and intellectual disability. NEAT1 is differentially expressed in TSC‐related epilepsy and influences neuronal excitability by regulating the PI3K/AKT/mTOR signaling pathway.
Suhui Kuang   +8 more
wiley   +1 more source

GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation

open access: yesAdvanced Science, EarlyView.
Schematic diagram of the mechanism by which GSK461364 inhibits NLRP3 inflammasome activation. GSK461364 inhibits the phosphorylation of NEK7 likely at serine 221 and serine 260 by suppressing the activity of PLK1, thereby restraining the formation of the NLRP3 inflammasome.
Ruiheng Luo   +13 more
wiley   +1 more source

ASOG: AntiSense Oligonucleotide Generator. [PDF]

open access: yesComput Struct Biotechnol J
Kimi J   +6 more
europepmc   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

open access: yesAdvanced Science, EarlyView.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy